6270-42-4

Usage

Uses

Used in Pharmaceutical Industry:
PIPERIDINE-4-CARBOXYLIC ACID DIMETHYLAMIDE HCL is used as a pharmaceutical intermediate for the synthesis of a range of medications. Its role in the creation of these medications is pivotal due to its ability to facilitate the development of new and effective treatments.
Used in Organic Synthesis:
In the field of organic synthesis, PIPERIDINE-4-CARBOXYLIC ACID DIMETHYLAMIDE HCL is utilized as a reagent, contributing to the formation of complex organic compounds. Its unique properties make it a valuable component in the synthesis process.
Used in Laboratory Research:
PIPERIDINE-4-CARBOXYLIC ACID DIMETHYLAMIDE HCL is also employed as a reagent in laboratory research, where its properties are explored and harnessed for scientific advancement. Its use in research aids in the discovery of new applications and understanding of chemical reactions and processes.

Upstream product

• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 254905-58-3 4-(dimethylcarbamoyl)piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS

Unsaturated nitrogen heterocyclic compounds of formula (I): (I), as defined in the specification, compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, Huntington's Disease, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

PHARMACEUTICAL COMPOUNDS

Fused pyrimidines of formula (I); wherein A represents a thiophene or furan ring; n is 1 or 2; R1 is a group of formula (II); wherein m is 0 or 1; R30 is H or C1-C6 alkyl; R4 and R5 form, together with the N atom to which they are attached, a 5- or 6-membered saturated N-containing heterocyclic group which includes 0 or 1 additional heteroatoms selected from N, S and O, which may be fused to a benzene ring and which is unsubstituted or substituted; or one of R4 and R5 is alkyl and the other is a 5- or 6-membered saturated N-containing heterocyclic group as defined above or an alkyl group which is substituted by a 5- or 6-membered saturated N-containing heterocyclic group as defined above; R2 is selected from formula (a); wherein R6 and R7 form, together with the nitrogen atom to which they are attached, a morpholine, thiomorpholine, piperidine, piperazine, oxazepane or thiazepane group which is unsubstituted or substituted; and formula (b); wherein Y is a C2-C4 alkylene chain which contains, between constituent carbon atoms of the chain and/or at one or both ends of the chain, 1 or 2 heteroatoms selected from O, N and S, and which is unsubstituted or substituted; and R3 is an indazole group which is unsubstituted or substituted; and the pharmaceutically acceptable salt thereof have activity as inhibitors of P13K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with P13 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.